Cidara Therapeutics Stock Price, News & Analysis (NASDAQ:CDTX)

$6.70 -0.10 (-1.47 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$6.70
Today's Range$6.60 - $6.99
52-Week Range$5.60 - $8.80
Volume48,400 shs
Average Volume75,879 shs
Market Capitalization$137.62 million
P/E Ratio-1.96
Dividend YieldN/A
Beta1.75

About Cidara Therapeutics (NASDAQ:CDTX)

Cidara Therapeutics logoCidara Therapeutics, Inc., formerly K2 Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections. Its product portfolio consists of over two formulations of its echinocandin, CD101. CD101 IV is a long-acting therapy for the treatment and prevention of serious, invasive fungal infections. CD101 topical, its second product candidate, is being developed for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC), a prevalent mucosal infection. Its immunotherapy technology platform, Cloudbreak, is used to create compounds designed to direct a patient's immune cells to attack and eliminate pathogens that cause infectious disease. The Company is also developing CD201, its bispecific antimicrobial immunotherapy.

Receive CDTX News and Ratings via Email

Sign-up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CDTX
CUSIPN/A
Phone858-752-6170

Debt

Debt-to-Equity Ratio0.16%
Current Ratio7.69%
Quick Ratio7.69%

Price-To-Earnings

Trailing P/E Ratio-1.95752365434219
Forward P/E Ratio-2.02
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$5.29 per share
Price / Book1.27

Profitability

Trailing EPS($3.40)
Net Income$-48,160,000.00
Net MarginsN/A
Return on Equity-82.17%
Return on Assets-65.11%

Miscellaneous

Employees60
Outstanding Shares20,240,000

Cidara Therapeutics (NASDAQ:CDTX) Frequently Asked Questions

What is Cidara Therapeutics' stock symbol?

Cidara Therapeutics trades on the NASDAQ under the ticker symbol "CDTX."

How were Cidara Therapeutics' earnings last quarter?

Cidara Therapeutics Inc (NASDAQ:CDTX) announced its quarterly earnings data on Wednesday, November, 8th. The biotechnology company reported ($0.73) earnings per share for the quarter, beating the consensus estimate of ($0.94) by $0.21. View Cidara Therapeutics' Earnings History.

Where is Cidara Therapeutics' stock going? Where will Cidara Therapeutics' stock price be in 2018?

9 equities research analysts have issued 1-year price targets for Cidara Therapeutics' stock. Their predictions range from $10.00 to $20.00. On average, they anticipate Cidara Therapeutics' stock price to reach $14.28 in the next twelve months. View Analyst Ratings for Cidara Therapeutics.

What are Wall Street analysts saying about Cidara Therapeutics stock?

Here are some recent quotes from research analysts about Cidara Therapeutics stock:

  • 1. Cantor Fitzgerald analysts commented, "We are positive on Cidara ahead of Phase 2 CD101 IV data (STRIVE study) for the treatment of systemic infections in early to mid-March. Our estimate on the timing of data release stems from the fact that the last patient, last visit (LPLV) was last week." (1/19/2018)
  • 2. According to Zacks Investment Research, "Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California. " (1/12/2018)
  • 3. Needham & Company LLC analysts commented, "Cidara mgmt provided a corporate update at an Investor Day in NYC last week and we separately hosted a series of mtgs w/ investors. Mgmt reiterated guidance for top-line results from ongoing Phase 2 trial of CD101 in Invasive Candida infections in 4Q17. The trial is expected to serve as the first of two registration trials. Given discontinuation of CD101 Vulvovaginal Candidiasis program, mgmt introduced plans to instead accelerate development in antifungal prophylaxis. KOLs highlighted differentiation from other echinocandins, w/ emphasis on PK/PD profile and opportunity for better clinical outcomes. New details around Cloudbreak candidates were also announced, although clinical testing not expected until 2018. Stock is attractive ahead of Phase 2 CD101 results later this year (EV $15M)." (4/10/2017)

Who are some of Cidara Therapeutics' key competitors?

Who are Cidara Therapeutics' key executives?

Cidara Therapeutics' management team includes the folowing people:

  • Scott M. Rocklage Ph.D., Chairman of the Board
  • Jeffrey L. Stein Ph.D., President, Chief Executive Officer, Director (Age 62)
  • Matthew W. Onaitis J.D., Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer, General Counsel, Secretary (Age 45)
  • Kenneth Bartizal Ph.D., Chief Development Officer (Age 63)
  • Paul Daruwala, Chief Commercial Officer (Age 46)
  • Kevin M. Forrest Ph.D., Chief Strategy Officer (Age 40)
  • Taylor Sandison M.D., Chief Medical Officer
  • Daniel D. Burgess, Director (Age 55)
  • Timothy R. Franson M.D., Director (Age 65)
  • Robert J. Perez, Director (Age 52)

When did Cidara Therapeutics IPO?

(CDTX) raised $60 million in an initial public offering (IPO) on Wednesday, April 15th 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow Life Sciences, Needham and BTIG were co-managers.

Who owns Cidara Therapeutics stock?

Cidara Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Prosight Management LP (8.14%), Broadfin Capital LLC (4.24%), Millennium Management LLC (2.93%), Renaissance Technologies LLC (0.89%), Guggenheim Capital LLC (0.51%) and Deutsche Bank AG (0.40%). Company insiders that own Cidara Therapeutics stock include Jeffrey Stein, Kevin Forrest, Target N V Biotech and Taylor Sandison. View Institutional Ownership Trends for Cidara Therapeutics.

Who sold Cidara Therapeutics stock? Who is selling Cidara Therapeutics stock?

Cidara Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Deutsche Bank AG, Guggenheim Capital LLC and Millennium Management LLC. View Insider Buying and Selling for Cidara Therapeutics.

Who bought Cidara Therapeutics stock? Who is buying Cidara Therapeutics stock?

Cidara Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Prosight Management LP, Eversept Partners LLC, Renaissance Technologies LLC and Broadfin Capital LLC. Company insiders that have bought Cidara Therapeutics stock in the last two years include Jeffrey Stein, Kevin Forrest, Target N V Biotech and Taylor Sandison. View Insider Buying and Selling for Cidara Therapeutics.

How do I buy Cidara Therapeutics stock?

Shares of Cidara Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cidara Therapeutics' stock price today?

One share of Cidara Therapeutics stock can currently be purchased for approximately $6.70.

How big of a company is Cidara Therapeutics?

Cidara Therapeutics has a market capitalization of $137.62 million. The biotechnology company earns $-48,160,000.00 in net income (profit) each year or ($3.40) on an earnings per share basis. Cidara Therapeutics employs 60 workers across the globe.

How can I contact Cidara Therapeutics?

Cidara Therapeutics' mailing address is 6310 NANCY RIDGE DRIVE SUITE 101, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-752-6170 or via email at [email protected]


MarketBeat Community Rating for Cidara Therapeutics (CDTX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  225 (Vote Outperform)
Underperform Votes:  152 (Vote Underperform)
Total Votes:  377
MarketBeat's community ratings are surveys of what our community members think about Cidara Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Cidara Therapeutics (NASDAQ:CDTX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $14.28$13.50$13.85$13.65
Price Target Upside: 98.35% upside87.50% upside68.90% upside121.95% upside

Cidara Therapeutics (NASDAQ:CDTX) Consensus Price Target History

Price Target History for Cidara Therapeutics (NASDAQ:CDTX)

Cidara Therapeutics (NASDAQ:CDTX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/19/2018Cantor FitzgeraldSet Price TargetBuy$15.00LowView Rating Details
11/9/2017HC WainwrightBoost Price TargetBuy$14.00 -> $16.00N/AView Rating Details
8/11/2017WBB SecuritiesUpgradeSell -> HoldLowView Rating Details
5/16/2017WedbushReiterated RatingOutperform$13.00LowView Rating Details
4/29/2017BTIG ResearchReiterated RatingBuy$15.00 -> $20.00LowView Rating Details
4/20/2017Raymond James FinancialInitiated CoverageStrong-Buy$14.00HighView Rating Details
4/12/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuy -> Buy$11.25LowView Rating Details
4/10/2017Needham & Company LLCReiterated RatingBuy$10.00MediumView Rating Details
3/24/2017Jefferies GroupReiterated RatingBuy$15.00HighView Rating Details
12/21/2016Leerink SwannInitiated CoverageOutperform$17.00N/AView Rating Details
(Data available from 2/23/2016 forward)

Earnings

Cidara Therapeutics (NASDAQ:CDTX) Earnings History and Estimates Chart

Earnings by Quarter for Cidara Therapeutics (NASDAQ:CDTX)

Cidara Therapeutics (NASDAQ CDTX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017Q3 2017($0.94)($0.73)$0.18 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.91)($0.99)$0.25 millionViewN/AView Earnings Details
5/10/2017Q1 2017($0.90)($0.80)ViewN/AView Earnings Details
3/15/2017Q4 2016($0.79)($0.88)ViewN/AView Earnings Details
11/10/2016Q3 2016($0.89)($0.88)ViewN/AView Earnings Details
8/11/2016Q2($0.76)($0.85)ViewN/AView Earnings Details
5/12/2016Q1($0.76)($0.71)ViewN/AView Earnings Details
3/18/2016Q4 2015($0.70)($0.72)ViewN/AView Earnings Details
11/16/2015Q3($0.57)($0.67)ViewListenView Earnings Details
8/11/2015Q2 2015($0.59)($0.59)ViewN/AView Earnings Details
5/21/2015Q1 2015($0.80)($5.92)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Cidara Therapeutics (NASDAQ:CDTX) Earnings Estimates

2018 EPS Consensus Estimate: ($2.86)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.78)($0.66)($0.72)
Q2 20182($0.79)($0.50)($0.65)
Q3 20182($0.80)($0.72)($0.76)
Q4 20182($0.87)($0.59)($0.73)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Cidara Therapeutics (NASDAQ:CDTX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Cidara Therapeutics (NASDAQ CDTX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 18.90%
Institutional Ownership Percentage: 59.51%
Insider Trades by Quarter for Cidara Therapeutics (NASDAQ:CDTX)
Institutional Ownership by Quarter for Cidara Therapeutics (NASDAQ:CDTX)

Cidara Therapeutics (NASDAQ CDTX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/15/2017Target N V BiotechMajor ShareholderBuy60,000$7.57$454,200.002,295,272View SEC Filing  
9/12/2017Jeffrey SteinCEOBuy7,350$6.79$49,906.5051,851View SEC Filing  
6/7/2017Taylor SandisonInsiderBuy20,000$5.90$118,000.00View SEC Filing  
6/5/2017Jeffrey SteinCEOBuy15,000$5.95$89,250.00View SEC Filing  
3/31/2017Jeffrey SteinCEOBuy12,900$7.75$99,975.00View SEC Filing  
3/31/2017Kevin ForrestInsiderBuy12,500$7.75$96,875.00View SEC Filing  
5/20/2016Jeffrey SteinCEOBuy4,310$11.51$49,608.1012,100View SEC Filing  
5/20/2016Kevin ForrestCFOBuy4,356$11.53$50,224.6858,253View SEC Filing  
11/25/2015Jeffrey SteinCEOBuy6,700$15.09$101,103.006,700View SEC Filing  
11/23/2015Kevin ForrestCFOBuy7,087$14.23$100,848.0151,719View SEC Filing  
4/20/2015Timothy R FransonDirectorBuy4,000$16.00$64,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Cidara Therapeutics (NASDAQ CDTX) News Headlines

Source:
DateHeadline
Reviewing Cidara Therapeutics (CDTX) & Paratek Pharmaceuticals (PRTK)Reviewing Cidara Therapeutics (CDTX) & Paratek Pharmaceuticals (PRTK)
www.americanbankingnews.com - February 19 at 3:20 PM
Cidara Therapeutics Inc (CDTX) Receives Average Rating of "Buy" from BrokeragesCidara Therapeutics Inc (CDTX) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - February 14 at 3:26 PM
The Antimicrobials Working Group Announces the Appointment of Dr. Michael Dunne as Vice ChairThe Antimicrobials Working Group Announces the Appointment of Dr. Michael Dunne as Vice Chair
finance.yahoo.com - January 30 at 3:19 PM
Cidara Therapeutics Announces Presentations at the 8th Advances Against Aspergillosis Conference and 2018 BMT Tandem MeetingCidara Therapeutics Announces Presentations at the 8th Advances Against Aspergillosis Conference and 2018 BMT Tandem Meeting
finance.yahoo.com - January 29 at 3:20 PM
Cidara Therapeutics Inc (CDTX) Receives Average Recommendation of "Buy" from BrokeragesCidara Therapeutics Inc (CDTX) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - January 20 at 5:38 PM
Cidara Therapeutics (CDTX) Stock Rating Reaffirmed by Cantor FitzgeraldCidara Therapeutics (CDTX) Stock Rating Reaffirmed by Cantor Fitzgerald
www.americanbankingnews.com - January 19 at 11:38 AM
Cidara Therapeutics (CDTX) Lowered to Hold at Zacks Investment ResearchCidara Therapeutics (CDTX) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - January 12 at 7:26 PM
Cidara Therapeutics (CDTX) Upgraded by Zacks Investment Research to "Buy"Cidara Therapeutics (CDTX) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - January 9 at 7:12 PM
Head-To-Head Contrast: Cidara Therapeutics (CDTX) versus Its CompetitorsHead-To-Head Contrast: Cidara Therapeutics (CDTX) versus Its Competitors
www.americanbankingnews.com - January 5 at 3:32 AM
Expansion Therapeutics Raises $55.3 Million in Series A Financing to Advance Portfolio of Novel RNA Targeted Small Molecule Medicines to Treat Rare DiseasesExpansion Therapeutics Raises $55.3 Million in Series A Financing to Advance Portfolio of Novel RNA Targeted Small Molecule Medicines to Treat Rare Diseases
www.businesswire.com - January 4 at 9:52 AM
Newly Published Journal of Antimicrobial Chemotherapy Supplement Provides Insights into the Future of Echinocandin Therapy for Invasive Fungal InfectionsNewly Published Journal of Antimicrobial Chemotherapy Supplement Provides Insights into the Future of Echinocandin Therapy for Invasive Fungal Infections
finance.yahoo.com - January 4 at 9:52 AM
Cidara Therapeutics Inc (CDTX) Given Consensus Recommendation of "Buy" by BrokeragesCidara Therapeutics Inc (CDTX) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - December 26 at 4:39 PM
Cidara Therapeutics (CDTX) Downgraded to Hold at Zacks Investment ResearchCidara Therapeutics (CDTX) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - December 25 at 7:14 PM
Analyzing Cidara Therapeutics (CDTX) and Its PeersAnalyzing Cidara Therapeutics (CDTX) and Its Peers
www.americanbankingnews.com - December 17 at 1:28 AM
Reviewing Cidara Therapeutics (CDTX) and Its RivalsReviewing Cidara Therapeutics (CDTX) and Its Rivals
www.americanbankingnews.com - December 12 at 8:48 AM
Cidara Therapeutics, Inc. (CDTX) Receives Consensus Recommendation of "Buy" from AnalystsCidara Therapeutics, Inc. (CDTX) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - December 2 at 12:00 AM
Cidara Therapeutics (CDTX) Completes Enrollment in Phase 2 STRIVE Trial Evaluating Novel Antifungal Rezafungin in Invasive Fungal InfectionsCidara Therapeutics (CDTX) Completes Enrollment in Phase 2 STRIVE Trial Evaluating Novel Antifungal Rezafungin in Invasive Fungal Infections
www.streetinsider.com - November 30 at 4:56 PM
Cidara Therapeutics Completes Enrollment in Phase 2 STRIVE Trial Evaluating Novel Antifungal Rezafungin (CD101 IV) in Invasive Fungal InfectionsCidara Therapeutics Completes Enrollment in Phase 2 STRIVE Trial Evaluating Novel Antifungal Rezafungin (CD101 IV) in Invasive Fungal Infections
finance.yahoo.com - November 28 at 4:55 PM
Cidara Therapeutics (CDTX) Given a $15.00 Price Target at Cantor FitzgeraldCidara Therapeutics (CDTX) Given a $15.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - November 28 at 11:20 AM
Cidara Therapeutics, Inc. (CDTX) Major Shareholder Target N. V. Biotech Buys 60,000 SharesCidara Therapeutics, Inc. (CDTX) Major Shareholder Target N. V. Biotech Buys 60,000 Shares
www.americanbankingnews.com - November 16 at 4:24 PM
Cidara Therapeutics Named a San Diego Metro Area 2017 Top WorkplaceCidara Therapeutics Named a San Diego Metro Area 2017 Top Workplace
finance.yahoo.com - November 13 at 11:11 PM
Cidara Therapeutics, Inc. (CDTX) Expected to Earn FY2017 Earnings of ($3.14) Per ShareCidara Therapeutics, Inc. (CDTX) Expected to Earn FY2017 Earnings of ($3.14) Per Share
www.americanbankingnews.com - November 13 at 3:58 AM
Cidara Therapeutics, Inc. (CDTX) Forecasted to Earn Q3 2018 Earnings of ($0.72) Per ShareCidara Therapeutics, Inc. (CDTX) Forecasted to Earn Q3 2018 Earnings of ($0.72) Per Share
www.americanbankingnews.com - November 10 at 4:20 PM
Edited Transcript of CDTX earnings conference call or presentation 8-Nov-17 9:05pm GMTEdited Transcript of CDTX earnings conference call or presentation 8-Nov-17 9:05pm GMT
finance.yahoo.com - November 9 at 7:53 PM
Cidara Therapeutics, Inc. (CDTX) Posts  Earnings Results, Beats Expectations By $0.21 EPSCidara Therapeutics, Inc. (CDTX) Posts Earnings Results, Beats Expectations By $0.21 EPS
www.americanbankingnews.com - November 9 at 12:44 AM
5 Biotech Stocks Well Poised to Surpass Expectations in Q35 Biotech Stocks Well Poised to Surpass Expectations in Q3
finance.yahoo.com - November 7 at 8:00 PM
Cidara Therapeutics, Inc. (CDTX) Receives Average Recommendation of "Buy" from BrokeragesCidara Therapeutics, Inc. (CDTX) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - November 6 at 5:48 PM
Cidara Therapeutics to Report Third Quarter 2017 Financial Results and Provide Corporate UpdateCidara Therapeutics to Report Third Quarter 2017 Financial Results and Provide Corporate Update
finance.yahoo.com - November 1 at 5:51 PM
Contrasting ADMA Biologics (ADMA) and Cidara Therapeutics (CDTX)Contrasting ADMA Biologics (ADMA) and Cidara Therapeutics (CDTX)
www.americanbankingnews.com - October 26 at 11:36 AM
Cidara Therapeutics, Inc. (CDTX) Raised to Buy at Zacks Investment ResearchCidara Therapeutics, Inc. (CDTX) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - October 25 at 5:26 PM
QURE On Fast Track, Music To CNCEs Ears, CRBP Gets A Facelift, OBLN DeflatedQURE On Fast Track, Music To CNCE's Ears, CRBP Gets A Facelift, OBLN Deflated
www.rttnews.com - October 19 at 10:36 PM
Cidara Therapeutics (CDTX) Prices $20M Private Placement of Common StockCidara Therapeutics (CDTX) Prices $20M Private Placement of Common Stock
www.streetinsider.com - October 19 at 10:36 PM
Cidara Therapeutics Announces Pricing of $20 Million Private Placement of Common StockCidara Therapeutics Announces Pricing of $20 Million Private Placement of Common Stock
finance.yahoo.com - October 19 at 5:34 PM
Contrasting Spark Therapeutics (ONCE) & Cidara Therapeutics (CDTX)Contrasting Spark Therapeutics (ONCE) & Cidara Therapeutics (CDTX)
www.americanbankingnews.com - October 19 at 12:16 AM
Cidara Therapeutics, Inc. (CDTX) Receives Consensus Rating of "Buy" from AnalystsCidara Therapeutics, Inc. (CDTX) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - October 12 at 6:56 PM
Cidara Therapeutics (CDTX) & Aradigm Corporation (ARDM) Critical AnalysisCidara Therapeutics (CDTX) & Aradigm Corporation (ARDM) Critical Analysis
www.americanbankingnews.com - October 10 at 9:07 AM
Cidara Therapeutics, Inc. (CDTX) Stock Rating Reaffirmed by Cantor FitzgeraldCidara Therapeutics, Inc. (CDTX) Stock Rating Reaffirmed by Cantor Fitzgerald
www.americanbankingnews.com - September 27 at 6:10 PM
Cidara Therapeutics Announces Presentations at IDWeek 2017 and the 8th Trends in Medical Mycology MeetingCidara Therapeutics Announces Presentations at IDWeek 2017 and the 8th Trends in Medical Mycology Meeting
finance.yahoo.com - September 25 at 7:44 PM
Cidara Therapeutics to Present at Two Upcoming ConferencesCidara Therapeutics to Present at Two Upcoming Conferences
finance.yahoo.com - September 18 at 8:37 PM
Cidara Therapeutics, Inc. (CDTX) CEO Acquires $49,906.50 in StockCidara Therapeutics, Inc. (CDTX) CEO Acquires $49,906.50 in Stock
www.americanbankingnews.com - September 12 at 8:24 PM
Cidara Therapeutics to Participate in Keynote Panel Discussion at the 2017 World Antimicrobial Resistance CongressCidara Therapeutics to Participate in Keynote Panel Discussion at the 2017 World Antimicrobial Resistance Congress
finance.yahoo.com - September 7 at 5:09 PM
Antimicrobials Working Group Member Companies Announce Partnership and Exclusive Pricing ProgramAntimicrobials Working Group Member Companies Announce Partnership and Exclusive Pricing Program
www.prnewswire.com - September 6 at 10:05 PM
Cidara Therapeutics, Inc. (CDTX) Short Interest Down 53.3% in AugustCidara Therapeutics, Inc. (CDTX) Short Interest Down 53.3% in August
www.americanbankingnews.com - August 28 at 1:20 AM
Brokers Issue Forecasts for Cidara Therapeutics, Inc.s Q3 2017 Earnings (CDTX)Brokers Issue Forecasts for Cidara Therapeutics, Inc.'s Q3 2017 Earnings (CDTX)
www.americanbankingnews.com - August 16 at 7:22 AM
Equities Analysts Offer Predictions for Cidara Therapeutics, Inc.s FY2018 Earnings (CDTX)Equities Analysts Offer Predictions for Cidara Therapeutics, Inc.'s FY2018 Earnings (CDTX)
www.americanbankingnews.com - August 14 at 9:22 AM
Leerink Swann Comments on Cidara Therapeutics, Inc.s Q3 2017 Earnings (NASDAQ:CDTX)Leerink Swann Comments on Cidara Therapeutics, Inc.'s Q3 2017 Earnings (NASDAQ:CDTX)
www.americanbankingnews.com - August 14 at 3:34 AM
Cidara Therapeutics (CDTX) Overweight Rating Reiterated at Cantor FitzgeraldCidara Therapeutics' (CDTX) Overweight Rating Reiterated at Cantor Fitzgerald
www.americanbankingnews.com - August 12 at 6:34 AM
Cidara Therapeutics, Inc. (CDTX) Upgraded to "Hold" at WBB SecuritiesCidara Therapeutics, Inc. (CDTX) Upgraded to "Hold" at WBB Securities
www.americanbankingnews.com - August 11 at 7:32 PM
Cantor Fitzgerald Analysts Give Cidara Therapeutics, Inc. (CDTX) a $15.00 Price TargetCantor Fitzgerald Analysts Give Cidara Therapeutics, Inc. (CDTX) a $15.00 Price Target
www.americanbankingnews.com - August 10 at 6:20 PM
Cidara Therapeutics Inc (NASDAQ:CDTX) Announces Quarterly  Earnings ResultsCidara Therapeutics Inc (NASDAQ:CDTX) Announces Quarterly Earnings Results
www.americanbankingnews.com - August 9 at 11:58 PM

SEC Filings

Cidara Therapeutics (NASDAQ:CDTX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Cidara Therapeutics (NASDAQ:CDTX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Cidara Therapeutics (NASDAQ CDTX) Stock Chart for Friday, February, 23, 2018

Loading chart…

This page was last updated on 2/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.